Accretion Pharmaceuticals Limited (NSE:ACCPL)
India · Delayed Price · Currency is INR 185.30
-8.65 (-4.46%)
At close: Oct 7, 2026
Accretion Pharmaceuticals Revenue
In the fiscal year ending March 31, 2026, Accretion Pharmaceuticals had annual revenue of 896.27M INR with 56.21% growth. Accretion Pharmaceuticals had revenue of 457.81M in the half year ending March 31, 2026. That makes Accretion Pharmaceuticals the world's 37,667th largest company by revenue and 3,291st in India.
Revenue
896.27M
Revenue Growth
+56.21%
P/S Ratio
2.30
Revenue / Employee
6.79M
Employees
132
Market Cap
2.06B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 896.27M | 322.51M | 56.21% |
| Mar 31, 2025 | 573.76M | 440.24M | 329.70% |
| Mar 31, 2024 | 133.53M | -161.79M | -54.79% |
| Mar 31, 2023 | 295.32M | 69.47M | 30.76% |
| Mar 31, 2022 | 225.84M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bilcare | 7.73B |
| Bal Pharma | 3.34B |
| Medico Remedies | 2.38B |
| Sat Kartar Life | 2.01B |
| Everest Organics | 1.92B |
| Gennex Laboratories | 1.78B |
| Kerala Ayurveda | 1.36B |
| Oxygenta Pharmaceutical | 1.35B |